PI
ESPR

PEAK6 Investments’s Esperion Therapeutics ESPR Stock Holding History

PEAK6 Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,177
Closed -$70K – 4126
2019
Q4 		$70K Sell
1,177
-12,616
-91% -$567K ﹤0.01% 2965
2019
Q3 		$506K Sell
13,793
-6,460
-32% -$256K ﹤0.01% 2264
2019
Q2 		$942K Sell
20,253
-1,187
-6% -$55.7K 0.01% 1812
2019
Q1 		$861K Buy
+21,440
New +$962K 0.01% 1963

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PEAK6 Investments's ESPR Position: Q1 2020 in Review

PEAK6 Investments sold out of Esperion Therapeutics (ESPR) in Q1 2020, closing a stake of 1,177 shares — an estimated $70K sold.

PEAK6 Investments first reported a position in ESPR in Q1 2019 and held it in 4 quarters. The position peaked at $942K in Q2 2019. 165 funds tracked by Wall St. Rank hold ESPR as of Q1 2020.

  • PEAK6 Investments reported no remaining Esperion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • PEAK6 Investments sold 1,177 Esperion Therapeutics shares in Q1 2020, an estimated $70K.
  • PEAK6 Investments first reported a position in Esperion Therapeutics in Q1 2019 and held it in 4 quarters.
  • PEAK6 Investments's Esperion Therapeutics position peaked at $942K in Q2 2019.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2020.

Based on PEAK6 Investments's 13F filing for Q1 2020, filed 14 May 2020.